OTTAWA, Nov. 17, 2011 /CNW/ - Annidis Corporation (TSX-V:RHA), creator
of the Annidis RHATM imaging technology that assists eye-care professionals screen, detect,
diagnose and manage ocular diseases, today announced that Dr. Robert G.
Devenyi, the Ophthalmologist-in-Chief and Director of Retinal Services
at the Donald K. Johnson Eye Center at the University Health Network
(UHN) has joined the Company's Board of Directors, and will replace Mr.
Tim McCunn as a Director.
Dr. Devenyi is also a Professor of Ophthalmology and Vision Sciences at
the University of Toronto, and the Team Ophthalmologist for the Toronto
Maple Leafs. He has worked at the Hospital for Sick Children, and been
on staff at the University Health Network since 1988.
"Robert comes from a very strong academic and industry background, and
his addition to our Board demonstrates his confidence in our unique
ocular pathology management system," said Mr. Mike Mueller, the
Chairman of Annidis Corporation. "During the year we have made a number
of strategic moves to develop a strong business platform, and with the
degree of experience and expertise Robert brings to our Board, we
believe we are well positioned to continue building momentum along our
aggressive growth path across Canada and the U.S."
"As a practicing ophthalmologist, I believe the RHA ocular pathology
management system has extensive clinical and research use, and could
develop to be a standard tool in diagnosing ocular disease," said Dr.
Devenyi. "My decision to join the Board of Annidis was primarily based
on my experience working with the RHA system, and was impressed by its
effectiveness in detecting and managing various ocular diseases."
Dr. Devenyi graduated summa cum laude from University of Toronto's
School of Medicine and completed his Ophthalmology residency at the
University of Toronto. He then did further training in the subspecialty
of Vitreoretinal Surgery at the Medical College of Wisconsin, in
In keeping with Annadis' compensation structure, Dr. Devenyi will not
receive any cash remuneration. Dr. Devenyi has been allocated stock
options for his service, which is part of the allocation of options
previously approved and reported in September 2011. This is in line
with the Company's policy, as the Directors, Chairman and CEO are all
compensated exclusively with options, which aligns their interest with
that of shareholders.
"On behalf of the Board, I'd like to thank Tim for his leadership and
contribution as a director for Annidis. The support he has provided to
the Company through our early stage to bring us where we are has been
invaluable." continued Mr. Mueller.
About Annidis Corporation
Annidis (TSX-V:RHA) is dedicated to researching and developing
instrumentation to assist in the early detection and monitoring of
diseases of the eye. The Company's RHATM is an ocular pathology management system that integrates advanced
multi-spectral imaging and analytic software for early detection and
management of ocular pathologies such as glaucoma, age-related macular
degeneration and diabetic retinopathy. The RHA system is the result of a multiyear research and development effort by the
Annidis team in collaboration with leading eye care professionals and
researchers in Canada including the Ottawa Eye Institute, Toronto
Western Hospital, the School of Optometry in Montreal and numerous
optometric clinics in Ontario.
This news release may contain "forward-looking information" within the
meaning of applicable Canadian securities legislation. Statements made
in this news release, other than those concerning historical financial
information, may be forward-looking and therefore subject to various
risks and uncertainties. The words "may", "will", "could", "should",
"would", "suspect", "outlook", "believe", "plan", "anticipate",
"estimate", "expect", "intend", "forecast", "objective", "hope", and
"continue" (or the negative thereof), and words and expressions of
similar import are intended to identify forward-looking statements.
Certain material factors or assumptions are implied in making
forward-looking statements and actual results may differ materially
from those expressed or implied in such statements. Factors that could
cause results to vary include those identified in the Company's Annual
Information Form and other such filings with Canadian securities
regulatory authorities, such as the applicability of patents and
proprietary technology; possible patent ligation; regulatory approval
of products in development; changes in government regulation or
regulatory approval processes; government and third party
reimbursement; dependence on strategic partnerships; intensifying
competition; rapid technological change in the industry; anticipated
future losses; the ability to access capital; and the ability to
attract and retain key personnel. All forward-looking information
presented herein should be considered in conjunction with such
filings. Except as required by Canadian securities laws, the
Corporation does not undertake to update any forward-looking
statements; such statements speak only as of the date made.
SOURCE Annidis Corporation
For further information:
Gerald Slemko, CEO
(416) 815-0700 ext. 264